Table 1 Description of the study population by the type of event (n = 70)
From: Ocular inflammatory events following COVID-19 vaccination: a multinational case series
Variable | Total (%) | Anterior Uveitis (%) | Posterior Uveitis (%) | Scleritis (%) | Others (%) | |
|---|---|---|---|---|---|---|
Demographics | Number of Patients | 70 (100.0) | 41 (58.6) | 9 (12.9) | 7 (10.0) | 13 (18.6) |
* Age (years) | 51 [19–84] | 55 [19–84] | 40 [28–61] | 48 [40–52] | 54 [25–79] | |
* Gender = Female | 35 (56.5) | 19 (52.8) | 4 (44.4) | 6 (85.7) | 6 (60) | |
* Gender = Male | 27 (43.5) | 17 (47.2) | 5 (55.6) | 1 (14.3) | 4 (40) | |
History of Previous COVID-19 | 1 (1.4) | 1 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Vaccine | Pfizer | 40 (57.1) | 20 (48.8) | 4 (44.4) | 5 (71.4) | 11 (84.6) |
Astra-Zeneca | 17 (24.3) | 12 (29.3) | 4 (44.4) | 1 (14.3) | 0 (0) | |
Moderna | 10 (14.3) | 7 (17.1) | 1 (11.1) | 1 (14.3) | 1 (7.7) | |
Sinopharm | 2 (2.9) | 1 (2.4) | 0 (0) | 0 (0.0) | 1 (7.7) | |
Covaxin | 1 (1.4) | 1 (2.4) | 0 (0) | 0 (0.0) | 0 (0) | |
Event After First Dose | Number of Patients | 43 (61.4) | 22 (53.7) | 6 (66.7) | 4 (57.1) | 11 (84.6) |
Time After First Dose [days] | 6 [1–14] | 5.5 [1–14] | 6.5 [1–14] | 4.5 [1–9] | 8 [1–14] | |
Received Another Dose | 18 (41.9) | 11 (50) | 3 (50) | 1 (25) | 3 (27.3) | |
Recurrence After Second Dose | 6 / 18 (33.3) | 5 / 11 (45.5) | 0 (0.0) | 1 / 4 (25.0) | 0 (0.0) | |
Event After Second Dose | Number | 27 (39.6) | 19 (46.3) | 3 (33.3) | 3 (42.9) | 2 (15.4) |
Time After Second Dose [days] | 5 [1–14] | 5 [1–14] | 8 [2–9] | 4 [2–14] | 7 [2–12] |